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Abstract: Over the past decade, a significant reduction in the prevalence of schistosomiasis has been
achieved, partially explained by the large-scale administration of praziquantel. Yet, the burden of
schistosomiasis remains considerable, and factors influencing intervention coverage are important.
This study aimed to deepen the understanding of low treatment coverage rates observed in two
schistosomiasis-endemic villages in Côte d’Ivoire. The research was conducted in August 2015,
in Moronou and Bigouin, two villages of Côte d’Ivoire that are endemic for Schistosoma haematobium
and S. mansoni, respectively. After completion of a clinical trial, standard praziquantel treatment
(single 40 mg/kg oral dose) was offered to all village inhabitants by community health workers
using a house-to-house approach. Factors influencing treatment coverage were determined by a
questionnaire survey, randomly selecting 405 individuals. The overall treatment coverage rate was
only 47.6% (2730/5733) with considerable intervillage heterogeneity (27.7% in Bigouin (302/1091)
versus 52.3% in Moronou (2428/4642)). Among the 200 individuals interviewed in Moronou,
50.0% were administered praziquantel, while only 19.5% of the 205 individuals interviewed in
Bigouin received praziquantel. The main reasons for low treatment coverage were work-related
(agricultural activities), the bitter taste of praziquantel and previous experiences with adverse events.
The most suitable period for treatment campaigns was reported to be the dry season. More than
three-quarter of the interviewees who had taken praziquantel (overall, 116/140; Moronou, 84/100;
Bigouin, 32/40) declared that they would not participate in future treatments (p < 0.001). In order
to enhance praziquantel treatment coverage, careful consideration should be given to attitudes and
practices, such as prior or perceived adverse events and taste of praziquantel, and appropriate timing,
harmonized with agricultural activities. Without such understanding, breaking the transmission of
schistosomiasis remains a distant goal.
Keywords: Côte d’Ivoire; coverage rate; praziquantel; preventive chemotherapy; Schistosoma
haematobium; Schistosoma mansoni
1. Introduction
Schistosomiasis is a widespread neglected tropical disease with a considerable public health
impact. Indeed, 779 million people are at risk of schistosomiasis, more than 250 million people are
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infected with blood flukes of the genus Schistosoma, and the global burden in 2016 was estimated
at 1.864 million disability-adjusted life years [1–3]. More than 90% of schistosome infections
are concentrated in Africa [1,4]. There is growing evidence of a positive relationship between
schistosome infections and subtle morbidity, including educational, learning and memory deficits [5].
The global strategy is morbidity control, emphasizing periodic administration of praziquantel to
at-risk populations without prior diagnosis. This strategy is phrased ‘preventive chemotherapy’
with the declared aim to achieve at least 75% of treatment coverage among school-aged children
in schistosome-endemic areas [6]. Efforts are underway to eliminate schistosomiasis as a public
health problem by 2025 [7–9]. In order to reach this ambitious goal, treatment with praziquantel
needs to be administered repetitively with high coverage, in concert with ancillary measures, such as
water, sanitation and hygiene (WASH), information, education and communication (IEC) and snail
control [10–15].
In Côte d’Ivoire, schistosomiasis control efforts have been intensified since 2006, yet were
challenged during periods of social unrest, armed conflict and war [16,17]. Starting in 2013,
with financial support from the Schistosomiasis Control Initiative (SCI) and other donors, regular
large-scale administration of praziquantel is under way, including sporadic assessment of treatment
coverage. However, factors influencing coverage rates and reasons for noncompliance have yet to be
systematically evaluated in Côte d’Ivoire.
In general, investigations that systematically evaluate treatment coverage and compliance of
the community are scarce [18–20]. Recent studies carried out in Uganda [18] and Zanzibar [19]
determined underlying factors responsible for low treatment compliance. The main reasons identified
by Knopp and colleagues for communities in Zanzibar not receiving or taking praziquantel were:
absence during drug distribution, no drug distributor reached the household, fear of adverse events,
pregnancy, breastfeeding or feeling healthy [19]. Moreover, lack of motivation or professional expertise
of drug distributors and limited information of the target population were associated with low
compliance of local communities with preventive chemotherapy [21,22]. Chami and colleagues
identified additional reasons for low compliance: They found that individuals of low socioeconomic
status, religious minorities and small tribes showed particularly low compliance rates with preventive
chemotherapy [18].
Within the frame of a randomized controlled trial conducted in two villages of central and
western Côte d’Ivoire that assessed the efficacy and safety of potential new treatments (i.e., Synriam®,
moxidectin and Synriam®–praziquantel) against schistosomiasis [12], there was an opportunity to
determine praziquantel treatment coverage rates. Indeed, after completion of the clinical trial, a single
40 mg/kg oral dose of praziquantel was offered to the communities. Low compliance was observed,
and hence, a questionnaire survey was conducted to identify reasons that might explain lack of
compliance. Here we present findings on attitudes and practices towards treatment of schistosomiasis
in the two study communities. Results and lessons might help to overcome current challenges in order
to achieve effective control and elimination of schistosomiasisin Côte d’Ivoire and other countries.
2. Material and Methods
2.1. Ethical Approval and Study Setting
The study was conducted in August 2015 during the rainy season, following completion of a
clinical trial assessing the efficacy and safety of Synriam® and moxidectin [12] against urogenital and
intestinal schistosomiasis in 256 school-aged children and adolescents (age: 12–17 years) in the villages
of Moronou (central Côte d’Ivoire) and Bigouin (western Côte d’Ivoire). As described elsewhere,
Moronou and Bigouin are highly endemic for Schistosoma haematobium and S. mansoni, respectively [12].
The clinical trial was approved by the Ethics Committee of Northwestern and Central Switzerland
(EKNZ; reference no. 15/01) and the Comité National d’Éthique et de la Recherche (CNER; reference
no. 026, approval date: 16 June 2015) of the Ministry of Health in Côte d’Ivoire. According to the last
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national census carried out in 2014, there were 4642 and 1091 inhabitants in Moronou and Bigouin,
respectively [23]. Informed oral consent was obtained from all participants for the questionnaire survey.
2.2. Sample Size Calculation
The sample size was assessed as recommended by Lemeshow et al. [24]. Briefly, we assumed
that 90% (P) of the individuals approached would answer the questionnaire with a relative precision
(d) of 5% and a level of confidence of 95% (Z = 1.96). The minimum sample size for each setting was
138 individuals, calculated as follows: n = Z21−α/2P(1 − P)/d2.
Allowing for 30% of absence during the door-to-door visit, approximately 200 individuals
(school-aged children, 6–15 years and adolescents/adults, ≥16 years) were randomly selected in
each village with equal numbers of treated and nontreated individuals during the door-to-door
treatment (as described below).
2.3. Praziquantel Treatment
Praziquantel tablets (Cesol® 600 mg) were offered free of charge to both communities following
the completion of a clinical trial (Figure 1). Communities were informed about the treatment days,
and the objectives, procedures and potential risks and benefits were explained. Village chiefs and
community leaders conducted an information meeting and, subsequently, the information was passed
on to the entire population. In both villages, a door-to-door approach was employed to administer
praziquantel over two consecutive days. In each village, a community health worker (CHW) was
recruited per neighborhood (six in Moronou and four in Bigouin). The CHWs were trained to treat
community members using a dose pole [25,26]. Villagers were invited to swallow the drug in front of
the CHWs. Related data, including name, sex, age and number of tablets administered, were recorded
in a register used by the national schistosomiasis control programme.
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2.4. Questionnaire Assessing Factors Influencing Treatment Compliance
A structured questionnaire was created, including data on demographics, main activities of the
participants, whether they had accepted the recent praziquantel treatment and factors that influenced
treatment compliance ( Supplementary file 1). We also gathered suggestions on how to improve the
distribution and administration of treatment in order to increase compliance. The questionnaire was
pretested in Abidjan, the economic capital of Côte d’Ivoire, among 15 randomly selected children
aged 9–12 years. CHWs were trained to implement the questionnaire. They were fluent in the local
language (i.e., Baoulé in Moronou and Yacouba in Bigouin). Translation of the questionnaire into local
languages was done for each study location. The questionnaire was implemented over 7 days in each
village, after the house-to-house treatment.
2.5. Statistical Analysis
Data were double entered into a database using EpiInfo version 3.5.1. (Centers for Disease
Control and Prevention, Atlanta, GA, USA). Data analysis was done using STATA version 12.1
(StataCorp., College Station, TX, USA). Qualitative (e.g., reasons for noncompliance) and quantitative
data (e.g., age and sex) were expressed as proportions and means, respectively. Proportions were
compared using Pearson’s chi-squared test (χ2). A p-value less than or equal to 0.05 was considered as
statistically significant.
3. Results
3.1. Treatment Compliance
Table 1 shows the praziquantel treatment coverage rate in Moronou and Bigouin. The overall
coverage rate was 47.6% (2730/5733) with considerable difference between the two villages (27.7% in
Bigouin (302/1091) versus 52.3% in Moronou (2428/4642)). While males reported significantly higher
treatment compliance in Bigouin (χ2 = 19.96, p < 0.001), no sex difference was observed in Moronou
(χ2 = 0.16, p = 0.104).
3.2. Factors Associated with Coverage of Praziquantel Treatment
Table 2 summarizes sex, age and occupation of the participants interviewed. The factors
influencing treatment compliance and suggestions on how treatment programmes could be improved
are presented in Table 3. In both settings we interviewed more males than females (248 versus 157)
with a statistically-significant difference observed in Bigouin (145 males versus 60 females; χ2 = 23.95,
p < 0.001). The main activity of the participants was farming with cash crops, particularly coffee,
cacao and hevea (53.5% in Moronou and 48.8% in Bigouin), followed by vegetables and rice (20.5% and
19.5%, respectively).
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Table 1. Praziquantel treatment coverage in Moronou and Bigouin, endemic respectively for Schistosoma haematobium and S. mansoni, in Côte d’Ivoire. The denominators
for the treatment coverage rate were derived from the 2014 national census.
Characteristic Total Population χ2 p No. of People Treated Treatment Coverage % χ2 p
Bigouin
Male 610 212 34.8
Female 481 10.19 0.001 90 18.7 19.96 <0.001
Total 1091 302 27.7
Moronou
Male 2397 1266 52.8
Female 2245 1162 51.8 0.16 0.104
Total 4642 3.32 0.069 2428 52.3
Total 5733 2730 47.6 85.39 <0.001
Table 2. Characteristics of study participants.
Participant Characteristics Moronou (n = 200) Bigouin (n = 205) Total (N = 405)
n (%) χ2 p n (%) χ2 p n (%) χ2 p
Sex
Female 97 (48.5) 60 (29.3) 157 (38.8)
Male 103 (51.5) 0.12 0.729 145 (70.7) 23.95 <0.001 248 (61.2) 13.71 <0.001
Average Age (SD)
6–15 years 11.9 (2.5) 11.3 (2.2) 11.6 (2.4)
≥16 years 36.6 (14.0) 40.1 (14.3) 38.4 (14.3)
Occupation
Cash crops (cocoa, coffee, hevea) (1) 107 (53.5) 100 (48.8) 207 (51.1)
Vegetable and rice crops (2) 41 (20.5) 40 (19.5) 81 (20.0)
Combined activities (1 & 2) 18 (9.0) 50 (24.4) 68 (16.8)
Other activity (trade, civil servant, etc.) 34 (17.0) 66.84 <0.001 15 (7.3) 57.15 <0.001 49 (12.1) 109.87 <0.001
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Table 3. Factors associated with praziquantel treatment coverage rates in Moronou and Bigouin, Côte d’Ivoire.
Associated Factor
Moronou (n = 200) Bigouin (n = 205) Total (N = 405)
n (%) χ2 p n (%) χ2 p n (%) χ2 p
Accepted Praziquantel Treatment (MDA)
Yes 100 (50.0) 40 (19.5) 140 (34.6)
No 100 (50.0) n.a. n.a. 165 (80.5) 53.00 <0.001 265 (65.4) 26.00 <0.001
Reason for Denial of Treatment n = 100 n = 165 n = 265
Not sick 4 (4.0) 13 (7.9) 17 (6.4)
Adverse events of previous treatment 25 (25.0) 3 (1.8) 28 (10.6)
Busy with field activities 70 (70.0) 148 (89.7) 218 (82.3)
Not informed about the treatment 1 (1.0) 87.42 <0.001 1 (0.6) 237.48 <0.001 2 (0.7) 306.93 <0.001
Reason of Treatment’s Acceptance n = 100 n = 40 n = 140
Sick 7 (7.0) 2 (5.0) 9 (6.4)
Knowledge on schistosomiasis/disease 68 (68.0) 11 (27.5) 79 (56.4)
Emulation 25 (25.0) 42.57 <0.001 27 (67.5) 17.86 <0.001 52 (37.1) 43.33 <0.001
What you did not like with the drug? n = 100 n = 40 n = 140
The taste 26 (26.0) 15 (37.5) 41 (29.3)
The size of the tablet 12 (12.0) 4 (10.0) 16 (11.4)
Adverse events 62 (62.0) 28.69 <0.001 21 (52.5) 8.98 <0.008 63 (45.0) 22.06 <0.001
Impact of the drug on your wellbeing n = 100 n = 40 n = 140
No effect 15 (15.0) 4 (10.0) 19 (13.6)
Improvement 85 (85.0) 34.55 <0.001 36 (90.0) 18.37 <0.001 121 (86.4) 52.65 <0.001
Could you accept a new treatment? n = 100 n = 40 n = 140
Yes 16 (16.0) 8 (20.0) 24 (9.2)
No 84 (84.0) 32.50 <0.001 32 (80.0) 10.00 <0.002 116 (44.4) 48.61 <0.001
Appropriate period for the treatment n = 200 n = 205 n = 405
Rainy season 2 (1.0) 7 (3.4) 9 (2.2)
Dry season 198 (99.0) 143.35 <0.001 198 (96.6) 131.30 <0.001 396 (97.8) 274.37 <0.001
Appropriate time for the treatment n = 200 n = 205 n = 405
Early in the morning 15 (7.5) 2 (1.0) 17 (4.2)
In the evening 14 (7.0) 26 (12.7) 40 (9.9)
At any time, if I am informed 171 (85.5) 164.12 <0.001 177 (86.3) 179.78 <0.001 348 (85.9) 340.58 <0.001
What is the best place to facilitate
treatment? n = 200 n = 205 n = 405
Central part of the village 16 (8.0) 78 (38.0) 94 (23.2)
House-to-house distribution 137 (68.5) 55 (26.8) 192 (47.4)
Health centre 47 (23.5) 84.39 <0.001 72 (35.1) 3.19 0.200 119 (29.4) 27.90 <0.001
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Half of the interviewees in Moronou (n = 100, 50%) and four out of five interviewees in
Bigouin (n = 165, 80.5%) did not take praziquantel during the treatment campaign. Farming activities
were stated as the main reason for not participating in the treatment (70%, 70/100 in Moronou;
89.7%, 148/165 in Bigouin). Other factors were adverse events experienced in previous treatment
campaigns (25.0%, 25/100 in Moronou) and a lack of treatment need (7.9%, 13/165 in Bigouin).
Additionally, 26.0% (26/100) of the participants in Moronou and 37.5% (15/40) in Bigouin complained
about the bitter taste of praziquantel as a reason for refusing treatment. Among the participants who
accepted the treatment, 62.0% (62/100) in Moronou and 52.5% (21/40) in Bigouin complained about
adverse events.
We were also interested in learning whether interviewees would accept another round of
praziquantel treatment and if so, whether they could give us some indications on the most appropriate
approach and timing for treatment. In both villages, among the individuals who were willing to accept
another treatment, three-quarters (overall 116/140; Moronou 84/100; Bigouin 32/40) declared that
they would not participate in a future treatment round (p < 0.001). Study participants recorded that in
both villages the most suitable period of the year for treatment campaigns would be the dry season.
There was no preferable time during the course of the day for the treatment. When asked about the
most suitable approach for the treatment delivery, in Moronou, two-third (68.5%, 137/200) suggested
a house-to-house approach as used in the current study (p < 0.001). There was no specific preference in
Bigouin (p = 0.200).
4. Discussion
Schistosomiasis is a neglected tropical disease that remains of considerable public health
relevance [3,27]. The cornerstone of schistosomiasis control is preventive chemotherapy, emphasising
periodic treatment of school-aged children with the declared aim to treat at least 75% of this age group
in schistosomiasis-endemic areas [7,8]. In view of new aspirations to eliminate schistosomiasis as
a public health problem and to break transmission, a range of activities, including broadening of
preventive chemotherapy along with WASH, IEC and snail control, are required [15,28,29]. Expanding
preventive chemotherapy programmes to the adult population calls for investigations of low treatment
coverage and compliance issues observed in several endemic areas that might undermine the success
of preventive chemotherapy [30].
Assessment of treatment compliance has been done mainly for mass drug administration
against lymphatic filariasis [21,31]. Only a few studies focused on schistosomiasis and intestinal
helminthiases [19,32,33]. Moreover, in Côte d’Ivoire, the factors influencing praziquantel coverage
rates have yet to be investigated.
We pursued a cross-sectional questionnaire survey to study factors that might explain low
treatment coverage in two selected villages in which a small clinical trial had been conducted before the
current study [12]. We employed a door-to-door approach with previously trained CHWs. While the
treatment compliance in Bigouin was very low (27.7%), it was considerably higher in Moronou (52.3%).
The main reason for not having received or taken praziquantel was farming activities at the time of drug
administration. Additional reasons were experience with adverse events from previous treatments
and the bitter taste of praziquantel. Although the bitter taste of praziquantel and adverse events are
well acknowledged in the literature [34–37], to our knowledge, studies evaluating the impact of these
issues on treatment compliance are scarce [35].
Previous studies assessing praziquantel treatment coverage reported varying compliance rates
and a host of factors influencing coverage. It might be worth highlighting that most of the data
reported thus far are based on systematic reviews, but only few have considered coverage as a study
objective and assessed it thoroughly using a questionnaire approach [19,38]. However, a standard
questionnaire used by the research teams to evaluate the factors influencing the treatment coverage is
lacking, rendering comparison from one location to another difficult [39–41].
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Advice has been given by the interviewed population to preferably implement preventive
chemotherapy in the dry season when farming activities are significantly reduced. Note that in Côte
d’Ivoire, as in other African countries, the rainy season is a period of intense farming activities. In that
period, a high proportion of the population is staying in small temporary hamlets, often inaccessible to
CHWs. It is clear that, while schoolchildren can be easily reached through the education system [42],
when extending the treatment to the entire community, socio–cultural issues, accessibility and main
occupational activities should be considered through a participatory approach [21]. Another factor
to be taken into account might be the duration of the intervention. Krentelet al. reported that in
some settings, the scheduled time for drug distribution was not sufficient to cover the entire target
population. Hence, one option would be to increase time dedicated to preventive chemotherapy and
to increase the number of CHWs distributing praziquantel. Yet, this suggestion was not made by the
people interviewed in the current investigation.
Our study has several limitations. First, the research was restricted to two rural settings of
central and western Côte d’Ivoire. In previous studies, distinctively different treatment compliance
rates were observed when comparing rural and urban settings; usually compliance in urban areas is
lower [21,31]. This was attributed mostly to a high proportion of migrants and mobile population,
private health institutions that discourage people from participating in preventive chemotherapy and
lack of a specific urban health strategy. Second, the treatment approach used by CHWs might differ
based on the size of the location. We found that in Moronou, which is approximately three times larger
than Bigouin, the population prefers a house-to-house approach. On the other hand, in Bigouin, no
preferable drug distribution emerged, as revealed by our questionnaire survey. As expected, treatment
needs by different populations vary and further investigations are required to elucidate this issue.
Third, we evaluated the current praziquantel treatment coverage rates shortly after the completion of a
small clinical trial in adolescents, assessing the efficacy and safety of different novel treatments and
treatment combinations against schistosomiasis, including praziquantel. Of note, during this trial only
a few participants from each community experienced adverse events, most of which were mild and
transient. Yet, it is conceivable that people experiencing adverse events or complaining of the bitter
taste of praziquantel might have influenced the willingness of the community members to participate
in the current mass treatment.
Only a few studies determined the impact of repeated preventive chemotherapy on treatment
compliance with praziquantel. In settings that underwent several years of mass drug administration,
such as in Zanzibar [19], Knopp et al. speculated on ‘treatment fatigue’ of the population being
only marginally infected, but repeatedly given medications. Similarly, in our study, we found
that most of the interviewees denied a subsequent treatment. This is an important issue, which
needs careful attention by disease control programme managers, since predictive models taking
into account prevalence and treatment coverage have shown that to reach elimination with mass
drug administration, at least 10 years of regular treatment with high treatment coverage (>70%)
is required [43]. In settings that aim at breaking transmission, integrated control approaches are
warranted, complementing preventive chemotherapy with WASH, IEC and snail control [44–46].
Such integrated control programmes require long-term commitment [47].
In conclusion, with schistosomiasis morbidity control progressively moving towards elimination,
and hence broadening preventive chemotherapy from school-aged children to include preschool-aged
children and adults, efforts should be made to regularly assess treatment coverage rates.
Since morbidity of schistosomiasis is often subtle and individuals might not feel sick, sensitization
prior to treatment should be carried out to diminish the reluctance of the population towards the
treatment caused by adverse events and the bitter taste of praziquantel. Particular attention should be
given to idiosyncrasies of endemic areas by taking into account timing and the mix of the intervention.
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